First trimester serum PAPP‐A and NGAL in the prediction of late‐onset pre‐eclampsia

D’Anna, Rosario; Baviera, G; Giordano, D.; Russo, Silvia; Dugo, Nella; Santamaria, Angelo; Corrado, Francesco

doi:10.1002/pd.2339

Cited by 46 publications

(27 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these data were not confirmed in another small series of 22 early PE cases in which the authors did not find any difference comparing PAPP-A MoM values in early PE and controls [8]. No differences were highlighted either in our previous study [9] carried out with late-onset PE cases. A better performance of this marker has been shown in a study carried out at 14-17 weeks of gestation, when the difference was reported to be significant with a good detection rate [10].…”

Section: Discussioncontrasting

confidence: 43%

Maternal Serum PAPP-A as an Early Marker of Obstetric Complications?

Quattrocchi¹,

Baviera²,

Pochiero³

et al. 2014

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: The aim of this study was to investigate whether low first-trimester PAPP-A levels are associated with an adverse pregnancy outcome. Materials and Methods: A retrospective case-control study was carried out using a Down's syndrome assays database over a 6-year period, between the 8th and 11th week of pregnancy. There were 164 women with PAPP-A multiples of median (MoM) levels <0.3 and 1,640 women with PAPP-A MoM levels ≥0.3 who served as a control group. Outcome measures were the prevalence of miscarriages, gestational hypertension, preeclampsia, pre-term delivery, gestational diabetes and intrauterine growth retardation in both groups. Results: The two groups significantly differed only for miscarriages: 29 (17.7%) vs. 159 (9.7%), p = 0.04, OR 1.7; gestational hypertension: 15 (9.1%) vs. 74 (4.5%), p = 0.02, OR 2.1, and preeclampsia: 9 (5.5%) vs. 29 (1.8%), p = 0.02, OR 2.5. Discussion: Even if in this study the PAPP-A cutoff considered was lower and was assayed in an earlier period compared with other studies, the detection rate for adverse pregnancy outcomes did not improve.

show abstract

Section: Discussioncontrasting

confidence: 43%

Maternal Serum PAPP-A as an Early Marker of Obstetric Complications?

Quattrocchi¹,

Baviera²,

Pochiero³

et al. 2014

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…Moreover, NGAL is not only present in the epithelial cells of the kidney, but also in epithelial cells of other end organs of preeclampsia such as the liver and lungs [16]. Indeed, studies in women with preeclampsia show that NGAL serum values are positively correlated with systolic and diastolic blood pressure and with proteinuria [17,18,19], suggesting a potential role as a predictive marker. NGAL has also been proposed as a first trimester screening marker for late PE [18,20].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Role of Maternal Neutrophil Gelatinase-Associated Lipocalin in Women with Severe Early-Onset Preeclampsia

et al. 2013

View full text Add to dashboard Cite

Introduction: The association between maternal plasma levels of neutrophil gelatinase-associated lipocalin (NGAL) and maternal complications in women admitted with severe early-onset preeclampsia was evaluated. Material and Methods: Plasma levels of NGAL were measured at admission in patients with severe early-onset (presenting before 34 weeks) preeclampsia. The maternal outcome of women with elevated plasma levels was compared with those with normal levels. Maternal complications included eclampsia, HELLP syndrome, acute renal failure, subcapsular hepatic hematoma, pulmonary edema and disseminated intravascular disease. Results: Sixty-seven patients were included. The median NGAL plasma levels in the group of women who subsequently had a complication were significantly higher than in those uncomplicated cases (114.8 vs. 84.2 ng/ml; Mann-Whitney U test p = 0.03). Maternal complications were more common in the elevated (>100 ng/ml) NGAL group (58.3 vs. 25.6%; χ² test p = 0.008), with an OR of 4.1 (95% CI 1.4-11.8). After adjustment by gestational age at onset, the association between elevated NGAL plasma levels and maternal complications remained significant (OR 4.2; 95% CI 1.4-12.4). Discussion: Women with severe early-onset preeclampsia are at higher risk of maternal complications if plasma levels of NGAL are elevated.

show abstract

“…This condition, characterized by the development of hypertension in or after the 20th week of pregnancy is associated with significant maternal and fetal complications. The elevated levels of NGAL in pre-eclampsia were positively correlated with both systolic and diastolic blood pressure and presence of proteinuria but showed a significant negative correlation with maternal age, pre-pregnancy BMI and weight (D'Anna et al, 2008;D'Anna et al, 2009b). Other conditions where NGAL levels are significantly elevated include atherosclerosis (Anwaar et al, 1998;Elneihoum et al, 1997;te Boekhorst et al, 2011) and hepatitis (Bu et al, 2006).…”

Section: Metabolic Diseasesmentioning

confidence: 99%